The University of Chicago Header Logo

Connection

Mark Talamonti to Immunotherapy, Active

Back to Details
This is a "connection" page, showing publications Mark Talamonti has written about Immunotherapy, Active.
Mark Talamonti
Connection Strength
0.112
Immunotherapy, Active
  1. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan; 17(1):94-100; discussion p. 100-1.
    View in: PubMed
    Score: 0.112
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.